魯西化工(000830.SZ):非公開發行股票方案獲中化集團批覆
格隆匯 8 月 24日丨魯西化工(000830.SZ)公佈,公司近日收到控股股東魯西集團有限公司(“魯西集團”)出具的《通知函》,獲悉中國中化集團有限公司(“中化集團”)《關於魯西化工集團股份有限公司非公開發行股份的批覆》(中化創新【2020】44號),具體批覆如下:
1、中化集團同意魯西化工非公開發行股份數量不超過439,458,233股(含),發行價格為7.50元/股,募集資金總額不超過3,295,936,747.50元(含),用於償還有息負債和補充流動資金。
2、同意中化投資發展有限公司以現金方式認購魯西化工本次非公開發行的全部股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.